Last reviewed · How we verify
89Zr-DFO-N-Suc-F8scFv
At a glance
| Generic name | 89Zr-DFO-N-Suc-F8scFv |
|---|---|
| Sponsor | Var2 Pharmaceuticals |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- PET-imaging of Two Vartumabs in Patients With Solid Tumors (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 89Zr-DFO-N-Suc-F8scFv CI brief — competitive landscape report
- 89Zr-DFO-N-Suc-F8scFv updates RSS · CI watch RSS
- Var2 Pharmaceuticals portfolio CI